Search | Médecins Sans Frontières Access Campaign

Search results for: driving medical innovation

21 results found
There are 0 active filters

21 results found

Maria Atonio, 43-years-old farmer from Macomia, returns home after visiting MSF’s Clinic in Nanga to receive ART treatment and to have a medical appointment with MSF’s clinical officer to monitor her health.

Press release |

06 February 2024

Colombia takes significant next step to expand people’s access to affordable HIV treatment, and moves forward with compulsory license for HIV medicine dolutegravir

MSF welcomes Colombia taking a historic next step towards issuing first-ever compulsory license to increase access to more affordable generic versions of key HIV medicine dolutegravir

Tags HIV/AIDS HIV/AIDS Medicines Patent PoolWorld Health OrganizationViiV

Statement |

13 March 2018

FP9 Public Consultation on EU funds in the area of investment, research & innovation, SME's and single market

Tags Research and development

Statement |

20 January 2017

MSF Written Submission to the Canadian House of Commons

Tags access to medicinesTrans-Pacific Partnership Agreement (TPP) Canada

Statement |

06 June 2016

MSF Remarks on Launch of O’Neill Report on Antimicrobial Resistance

Tags Antimicrobial resistance antimicrobial resistance pneumococcal conjugate vaccine research and development (R&D)

Statement |

07 April 2016

MSF Written Submission to the Australian Parliament

Tags Trans-Pacific Partnership Agreement (TPP) Australia

Statement |

04 April 2016

Submission for US International Trade Commission Investigation

Tags Trans-Pacific Partnership Agreement (TPP)

Statement |

08 December 2015

MSF's Oral Testimony to the United States House of Representatives Committee on Ways and Means

Tags Intellectual property and trade

MSF doctor Christoph Höhn performs an eye test on 16-year-old patient Shahnoza in her family home. Shahnoza started MDR-TB treatment in October 2012 but was later diagnosed with XDR-TB. Since January 2013, she is on the right drug regimen, but she will ne

Press release |

30 October 2014

MSF sounds alarm on practices and policies dangerously out of step with what’s needed to contain the global drug-resistant TB crisis

Tags Tuberculosis drug-resistant TBtuberculosis

Opinion article |

02 October 2014

Why We Need Open Source Pharma

Tags Research and development access to medicines

Statement |

05 December 2013

Best Science for the Most Neglected: What can we learn from the DNDi model at 10 years?

Tags Tropical & neglected diseases neglected diseases DNDi

Opinion article |

19 August 2013

Global Health – Keeping medicines affordable for all

Tags Trans-Pacific Partnership Agreement (TPP)free trade agreement Canada

Opinion article |

19 August 2013

Patients Before Patents

Tags Trans-Pacific Partnership Agreement (TPP)free trade agreement Australia

Statement |

24 May 2013

MSF intervention on R&D Financing & Coordination at 66th WHA

Tags Research and development CEWGresearch and development (R&D) World Health AssemblyWorld Health Organization

Speech |

16 May 2013

DNDi at ten: past success, future challenges

Tags Intellectual property and tradeResearch and developmentTropical & neglected diseases neglected diseases DNDi

Press release |

12 December 2012

Millions of Patients Still Waiting for Medical “Breakthroughs” Against Neglected Diseases

Tags HIV/AIDSIntellectual property and tradeResearch and developmentTropical & neglected diseasesTuberculosisVaccines neglected diseasessleeping sicknessvisceral leishmaniasis (kala azar) research and development (R&D)

Letter |

27 November 2012

Open letter to WHO Member States at follow-up meeting on the report of the CEWG

Tags Intellectual property and tradeResearch and development CEWGresearch and development (R&D) World Health AssemblyWorld Health Organization

Speech |

25 November 2012

MSF Intervention at Member States follow-up meeting on CEWG, November 2012

Tags HIV/AIDSIntellectual property and tradeResearch and developmentTuberculosisVaccines CEWGresearch and development (R&D)

Speech |

09 October 2012

MSF Keynote Address at 2012 J. William Fulbright Prize for International Understanding

Tags HIV/AIDSIntellectual property and tradeMalariaMalnutritionTropical & neglected diseasesTuberculosisVaccines sleeping sickness research and development (R&D) DNDi

Opinion article |

28 June 2012

Promoting long term adherence to antiretroviral treatment Patient support and community interventions are probably the best interventions

Tags HIV/AIDS HIV/AIDS

Feature story |

20 December 2006

Q&A on patents in India and the Novartis case

Tags Intellectual property and trade antiretroviral medicinesimatinib Novartis Novartis Drop the Case Campaign India

Search results for: driving medical innovation

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

Colombia takes significant next step to expand people’s access to affordable HIV treatment, and moves forward with compulsory license for HIV medicine dolutegravir

FP9 Public Consultation on EU funds in the area of investment, research & innovation, SME's and single market

MSF Written Submission to the Canadian House of Commons

MSF Remarks on Launch of O’Neill Report on Antimicrobial Resistance

MSF Written Submission to the Australian Parliament

Submission for US International Trade Commission Investigation

MSF's Oral Testimony to the United States House of Representatives Committee on Ways and Means

MSF sounds alarm on practices and policies dangerously out of step with what’s needed to contain the global drug-resistant TB crisis

Why We Need Open Source Pharma

Best Science for the Most Neglected: What can we learn from the DNDi model at 10 years?

Global Health – Keeping medicines affordable for all

Patients Before Patents

MSF intervention on R&D Financing & Coordination at 66th WHA

DNDi at ten: past success, future challenges

Millions of Patients Still Waiting for Medical “Breakthroughs” Against Neglected Diseases

Open letter to WHO Member States at follow-up meeting on the report of the CEWG

MSF Intervention at Member States follow-up meeting on CEWG, November 2012

MSF Keynote Address at 2012 J. William Fulbright Prize for International Understanding

Promoting long term adherence to antiretroviral treatment Patient support and community interventions are probably the best interventions

Q&A on patents in India and the Novartis case